Alnylam Pharmaceuticals | ALNY - Marktkapitalisierung

Aktienkurs
330.34
Täglich Wechseln
11.49 3.60%
Monatlich
2.09%
Jährlich
41.81%
Q2 Prognose
309.25




Marktkapitalisierung Veränderung Datum
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
Agios Pharmaceuticals USD 1.59B 745M 2025-12
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amgen USD 176.25B 24.32B 2025-12
Arrowhead Research USD 9.02B 4.25B 2025-12
BioCryst Pharmaceuticals USD 1.66B 64M 2025-12
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Incyte USD 19.39B 2.83B 2025-12
Ionis Pharmaceuticals USD 12.81B 2.39B 2025-12
Neurocrine Biosciences USD 14.14B 218M 2025-12
Novartis USD 263.08B 17.01B 2025-12
PTC Therapeutics USD 6.1B 1.22B 2025-12
Regeneron Pharmaceuticals USD 81.12B 21.53B 2025-12
Sanofi EUR 117.34B 2.45B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
Takeda JPY 7.64T 774.9B 2025-12
Tectonic Therapeutic USD 390M 96M 2025-12
Ultragenyx Pharmaceutical USD 2.22B 680M 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12
Xencor USD 1.09B 256M 2025-12